Knowledge Topic

Designing a Governed Manufacturing Agent Workflow: Retrieval, Escalation, Human Review, and Evidence

A governed manufacturing agent workflow controls what an agent may retrieve, what evidence it must present, when it must escalate, and which qualified person remains accountable for the final decision.

Industry context

The OWASP Top 10 for Agentic Applications 2026 identifies ten major risk categories for systems that plan, retrieve, use tools, and coordinate multistep work. The list includes goal hijacking, tool misuse, identity and privilege abuse, memory poisoning, cascading failures, and rogue-agent behavior (OWASP Foundation, 2025).

At a glance

A governed manufacturing agent workflow is more than a prompt followed by an approval button. It is a controlled path from a user’s question to permission-aware retrieval, evidence preparation, risk checks, escalation, human review, and an auditable outcome.

The workflow begins with a narrow intended use. The organization defines the users, approved data sources, allowed actions, prohibited actions, required evidence, accountable reviewer, and conditions that force the agent to stop.

Retrieval must respect role-based access, source authority, plant and asset scope, time boundaries, document versions, and data freshness. The output should be an evidence packet, not only a written answer. It should show what was asked, which records were used, what was missing or conflicting, how the recommendation was formed, and who must review it.

Escalation rules should be explicit. Missing evidence, stale data, restricted information, source conflicts, unusual operating conditions, and consequential decisions should route the work to a qualified person.

Meaningful human review gives that person the information, authority, and options required to accept, correct, reject, or escalate the output. Each action should be recorded.

The result is not uncontrolled autonomy. It is faster evidence preparation inside a workflow where people retain responsibility for quality, compliance, safety, production, maintenance, and customer-impacting decisions.

On this page

Overview

Those risks make one point clear: governance cannot be added after the workflow has been built.

A governed manufacturing workflow should follow a visible, testable path:

Question → Identity check → Scope resolution → Approved retrieval → Evidence packet → Risk check → Escalation or human review → Recorded outcome

Each stage needs an owner, control, expected output, failure condition, and recovery path.

Three workflow failures governance must prevent

Retrieval can return real information from the wrong context

An agent may retrieve a valid record and still produce the wrong conclusion. The record might belong to another plant, asset, product, supplier, lot, or time window.

The agent may also use an obsolete procedure, a superseded drawing, a retired historian tag, or a field the current user is not authorized to see. A fluent summary can hide these errors because the answer may still sound operationally reasonable.

Governed retrieval must apply access and scope controls before information reaches the reasoning or synthesis stage. It should verify identity, source approval, document status, plant hierarchy, asset mapping, effective dates, and data freshness.

The ISA-95 standard provides a shared framework for integrating enterprise and manufacturing control systems. It is useful for agent workflow design because it helps teams define which systems own planning, operations management, supervision, and control information (International Society of Automation, current).

An agent that prepares evidence across Manufacturing Execution System, Enterprise Resource Planning, historian, maintenance, and document sources should respect those boundaries. It should not quietly turn an evidence workflow into a direct equipment-control workflow.

Vague escalation rules create dangerous silence or constant noise

“Escalate when needed” is not an operational rule.

Without explicit triggers, the agent may continue when a required source is unavailable, when evidence conflicts, or when a request exceeds its intended use. The opposite problem is alert overload. If every small variation becomes a critical alert, reviewers will stop treating escalation as meaningful.

A governed workflow should define:

Which conditions produce an informational note

Which conditions require reviewer attention

Which conditions stop the current task

Which conditions suspend the saved routine

Who receives each escalation

How quickly the recipient must respond

What evidence accompanies the escalation

Who may authorize reactivation

The severity should reflect consequence, not only model confidence. A high-confidence answer with the wrong plant scope is still wrong. A lower-confidence summary with complete evidence may still be useful if it is clearly labeled and routed appropriately.

Human review can become a cosmetic approval step

A person clicking “approve” does not prove meaningful human oversight.

The reviewer must understand the intended use, see the supporting evidence, recognize uncertainty, and have authority to correct, reject, override, pause, or escalate the output. The person also needs enough time to perform the review.

Article 14 of the EU AI Act requires human-oversight measures for high-risk AI systems that allow people to understand system capabilities and limitations, interpret outputs, remain alert to overreliance, and intervene or stop the system where appropriate (European Parliament and Council of the European Union, 2024).

Not every manufacturing agent will fall within the Act’s high-risk categories. The oversight principles still provide a useful design test: can the assigned person understand, challenge, override, and stop the workflow?

For pharmaceutical use cases, the related Annex 22 and human-in-the-loop Knowledge Topic should explain the additional good manufacturing practice context without turning this general workflow article into legal advice.

Ask this → Get that

Ask This → Get That: Build the workflow step by step

Ask this

“What exact task does the agent support?”

Get

A bounded intended-use statement.

A useful statement identifies:

Intended users
Business process
Approved systems
Permitted retrieval
Allowed recommendations
Prohibited actions
Required evidence
Human-review role
Escalation triggers
Workflow owner
Suspension authority
For example:

Retrieve production, maintenance, historian, and current procedure evidence associated with an equipment excursion, then prepare a non-binding summary for quality review.

Avoid mandates such as “manage quality,” “optimize maintenance,” or “support batch release.” Those phrases are too broad to validate and too vague to govern.

The ISO/IEC 42001 AI management-system model reinforces the importance of defined responsibilities, policies, risk controls, performance evaluation, and continual improvement around AI use (International Organization for Standardization, 2023).

Ask this

“Which information may the agent retrieve?”

Get

A permission-aware retrieval map.

The map should identify:

Source system
Authoritative owner
Approved tables, fields, documents, and signals
Read-only or write capability
Plant, line, asset, product, and lot scope
Time-window rules
Role and column restrictions
Document status requirements
Freshness limits
Mapping owner
Failure response

Apply access control before retrieval and before synthesis. Do not retrieve broad information and attempt to remove restricted content after the model has already processed it.

NIST Special Publication 800-207, Zero Trust Architecture, shifts access decisions away from implicit network trust and toward users, assets, resources, and explicit policy. That approach is highly relevant to manufacturing agents because an agent should be treated as a controlled identity with defined permissions and a revocation path (Rose et al., 2020).

Ask this

“What must the reviewer see?”

Get

A structured evidence packet.

The packet should contain:

Original question or event
User identity and role
Plant, asset, product, lot, and time scope
Records and documents retrieved
Source names, timestamps, and versions
Relevant events, trends, and comparisons
Missing, stale, or conflicting evidence
Agent summary or recommendation
Required human-review action
Audit and workflow identifiers

Do not hide conflicting evidence. A disagreement between a maintenance record and a historian event may be the most important finding in the packet.

In regulated drug manufacturing, the PIC/S Good Practices for Data Management and Integrity emphasizes data that is attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, and available. These principles are useful when defining the evidence quality expected from agent-supported workflows (Pharmaceutical Inspection Co-operation Scheme, 2021).

Ask this

“When must the workflow escalate or stop?”

Get

An explicit decision table.

Escalation should include the evidence already collected. Sending only an alert forces the next person to reconstruct the problem.

Ask this

“What can the human reviewer do?”

Get

Meaningful decision options.

The reviewer should be able to:

Accept the evidence packet for its permitted purpose
Correct the scope or summary
Reject the recommendation
Request more evidence
Assign another reviewer
Escalate to another function
Record a reason
Pause the routine
Stop or revoke the workflow

Record the reviewer’s identity, role, evidence viewed, decision, comments, and timestamp.

Where the workflow creates or supports regulated electronic records, teams should assess the applicability of 21 CFR Part 11. Part 11 addresses controls for trustworthy electronic records and electronic signatures, including system controls, record protection, access, and signature linkage (Electronic Code of Federal Regulations, current).

Ask this

“What happens when a defect is discovered?”

Get

A containment and recovery procedure.

A practical sequence is:

Pause the affected routine
Preserve the current audit record
Notify the workflow, system, and security owners
Identify outputs produced during the affected period
Determine whether decisions must be reviewed
Correct the defect
Retest the failed control
Document the result
Obtain authorization before reactivation

The workflow should be interruptible by design. A routine that cannot be suspended safely is not ready for operational use.

Security testing should also consider agent-specific risks. The OWASP agentic security framework identifies privilege abuse, unsafe tool use, goal manipulation, insecure communication, memory compromise, and cascading failure as important control areas (OWASP Foundation, 2025).

Illustrative example

Example Case Study – How the Solution Benefits

This is an illustrative example.

Problem: A plant completed 40 deviation investigations each month. A quality engineer spent an average of 90 minutes gathering records from the Manufacturing Execution System, Quality Management System, maintenance system, historian, and document repository before formal review could begin.

Approach: The team designed a bounded evidence-preparation workflow. The agent could retrieve approved records, apply plant and role scope, verify procedure status, display source links, flag conflicts, and route the packet to quality. It could not classify the deviation, close the record, make a disposition decision, or alter validated information.

Result: Evidence-preparation time fell from 90 minutes to 20 minutes per investigation. Across 40 monthly investigations, the plant recovered about 47 expert hours per month. Every evidence packet contained its scope, sources, unresolved gaps, assigned reviewer, and recorded outcome.

The benefit did not come from removing the quality decision. It came from reducing manual evidence assembly while preserving accountable human review.

Common questions

Frequently asked questions

Should a manufacturing agent ever take action automatically?

Low-risk and reversible actions may be appropriate within an approved workflow, such as preparing a draft work item or sending a notification. Actions that affect product quality, safety, regulated records, equipment control, batch disposition, deviation closure, or customer commitments should remain inside a controlled human decision process. The intended use and risk assessment should define the exact boundary.

What makes human review meaningful?

The reviewer must be qualified, have access to the supporting evidence, understand the workflow’s intended use and limits, and possess authority to accept, correct, reject, override, pause, or escalate the output. The system should record what the reviewer saw, what the person decided, and why. A passive approval button without evidence, competence, or intervention authority is not meaningful oversight.

Next step

Governed Manufacturing Agent Workflow Design Canvas

Use a Governed Manufacturing Agent Workflow Design Canvas to define retrieval boundaries, evidence requirements, escalation triggers, reviewer authority, audit events, pause controls, and reactivation responsibility.

To evaluate this design against a real quality, maintenance, downtime, yield, or root-cause workflow, explore the Connected Manufacturing 90-Day Design Partner Program.

Sources

References

Electronic Code of Federal Regulations. (Current). 21 CFR Part 11: Electronic records; electronic signatures.
Part 11 defines criteria and controls associated with electronic records and electronic signatures in applicable FDA-regulated contexts. The eCFR is the continuously updated online presentation of the United States Code of Federal Regulations. This source supports the article’s discussion of record trustworthiness, system controls, identity, auditability, and signature-to-record linkage.
European Parliament and Council of the European Union. (2024). Regulation (EU) 2024/1689 laying down harmonised rules on artificial intelligence.
The regulation establishes the European Union’s risk-based legal framework for artificial intelligence, including human-oversight requirements for high-risk systems. EUR-Lex is the European Union’s official access point for EU law and provides the primary legal text. The regulation supports the article’s explanation that meaningful oversight should enable people to interpret, challenge, override, and stop applicable AI systems.
International Society of Automation. (Current). ISA-95 Standard: Enterprise-control system integration.
ISA-95 defines models and terminology for integrating enterprise and manufacturing control-system functions. ISA is the professional standards body responsible for the ANSI/ISA-95 family, which is also aligned with IEC 62264. The source supports the article’s recommendations for maintaining system boundaries, data ownership, manufacturing context, and separation between evidence workflows and direct process control.
National Institute of Standards and Technology. Rose, S., Borchert, O., Mitchell, S., & Connelly, S. (2020). NIST SP 800-207: Zero Trust Architecture.
This publication describes zero-trust principles that focus access decisions on users, assets, resources, and explicit policy rather than assumed network trust. NIST is a United States government standards agency, and SP 800-207 is a widely adopted primary cybersecurity reference. The publication supports the article’s guidance on treating agents as controlled identities with least-privilege permissions, policy enforcement, logging, and revocation paths.
OWASP Foundation. (2025). OWASP Top 10 for Agentic Applications for 2026.
This resource identifies security risks associated with agents that pursue goals, call tools, access information, and coordinate multistep workflows. OWASP is a nonprofit software security organization whose resources are created through open collaboration among security practitioners and researchers. The source supports workflow controls for goals, tools, identity, privileges, memory, communications, cascading failures, and containment.
Pharmaceutical Inspection Co-operation Scheme. (2021). Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments, PI 041-1.
This guidance describes data governance and integrity expectations across paper, electronic, and hybrid systems in regulated good manufacturing practice and good distribution practice environments. PIC/S is an international cooperation framework among pharmaceutical inspection authorities and is an authoritative source for inspection-oriented GMP guidance. The document supports the article’s evidence-packet requirements for complete, accurate, consistent, attributable, enduring, available, and lifecycle-controlled records.
World Wide Web Consortium. (2024). Web Content Accessibility Guidelines 2.2.
WCAG 2.2 provides testable recommendations for making web content and interfaces more accessible to people with disabilities. The World Wide Web Consortium develops internationally recognized technical standards for the web through an open consensus process. The source supports the article’s accessibility requirements for workflow diagrams, evidence displays, dashboards, review controls, text alternatives, contrast, labels, and keyboard operation.